Latest Video Updates

Upcoming Oncology Education Events

OncologyEducation Events Video Archives

Oncology Clinical News

Updated Data Confirms a Durable 75 Percent Overall Response Rate, by Blinded Independent Review, of Larotrectinib in Adults and Children with Tumors Harboring TRK Fusions

(MSK) Feb 21, 2018 - Larotrectinib, a highly selective TRK kinase inhibitor, shows rapid, potent, and durable efficacy in both adult and pediatric patients with solid tumors that harbor TRK fusions, regardless of tumor type or patient age, according to results from three clinical trials published in the New England Journal of Medicine.
Read full article.

(Morningstar) Feb 21, 2018 - Mesoblast Limited today announced that the Phase 3 trial of its allogeneic mesenchymal stem cell product candidate MSC-100-IV (remestemcel-L) in children with steroid refractory acute Graft versus Host Disease (aGVHD) has successfully met the primary endpoint of Day 28 overall response (OR, complete + partial response) rate.
Read full article.

Gilead Signs $3 Billion Licensing Deal For Sangamo's Gene-Editing Platform


Read full article.

Powered by OBR Oncology